Security Snapshot

Entera Bio Ltd. - Ordinary Shares, par value NIS 0.0000769 (ENTX) Institutional Ownership

CUSIP: M40527109

13F Institutional Holders and Ownership History from Q2 2018 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

35

Shares (Excl. Options)

122.29MFull value: 122,291,982 · shares · 30 Sep 2026

Price

$2.91

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+112,091,170
Value change
+$326,240,700
Number of holders
35
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
175,210,234
SEC-reported price per share
$3.12
Insider filing price
$3.12
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • ENTX - Entera Bio Ltd. - Ordinary Shares, par value NIS 0.0000769 is tracked under CUSIP M40527109.
  • 35 institutions reported positions in Q3 2026.
  • 9 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 27 to 35 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $18.99MFull value: $18,985,880 · USD · 30 Jun 2026
    to
    $355.87MFull value: $355,869,666 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 35 institutions filings for Q3 2026.

Open SEC evidence

Security key

M40527109

13F reference period

Q3 2026

13F holders

35

13D/G owners

9

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
9
Security
ENTX
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BIOTECHNOLOGY VALUE FUND L P 10% $28,593,701 17,225,121 BVF PARTNERS L P/IL 28 Jul 2026
TCG Crossover GP III, LLC 7.1% $20,343,136 12,254,901 TCG Crossover GP III, LLC 28 Jul 2026
Vivo Opportunity Fund Holdings, L.P. 6.9% $19,616,886 11,817,401 Vivo Opportunity, LLC 28 Jul 2026
Spruce Street Capital LP 6.4% $27,921,503 11,213,455 Spruce Street Capital LP 30 Sep 2026
Venrock Healthcare Capital Partners III, L.P. 5.1% $26,186,510 8,861,763 Venrock Healthcare Capital Partners III, L.P. 23 Oct 2026
Longitude Capital Partners V, LLC 4.6% $13,019,609 7,843,138 Longitude Capital Partners V, LLC 28 Jul 2026
Seven Fleet Capital Management LP 4.1% $11,709,471 7,053,898 Seven Fleet Capital Management LP 28 Jul 2026
OPKO HEALTH, INC. 8.1% $8,660,281 3,685,226 OPKO HEALTH, INC. 16 Mar 2025
Point72 Asset Management, L.P. 2.6% -60% $2,271,583 -$2,915,412 1,183,116 -56% Point72 Asset Management, L.P. 30 Sep 2025
As of 30 Sep 2026, 35 institutional investors reported holding
122.29MFull value: 122,291,982 · shares · 30 Sep 2026
shares of Entera Bio Ltd. - Ordinary Shares, par value NIS 0.0000769 (ENTX). This represents 70% of the company’s total
175.21MFull value: 175,210,234 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
69%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BVF INC/IL 9.7% 17,052,893 1.6% $49,623,919
Vivo Capital, LLC 7% 12,254,901 3.9% $35,661,762
TCG Crossover Management, LLC 7% 12,254,901 1% $35,661,762
Spruce Street Capital LP 6.4% 11,213,455 5.2% $32,631,154
Commodore Capital LP 4.2% 7,352,941 1.7% $21,397,058
Seven Fleet Capital Management LP 3.9% 6,862,744 3.9% $19,970,585
Siren, L.L.C. 3.4% 6,000,000 0.41% $17,460,000
Knoll Capital Management, LLC 3.3% 5,832,038 8.1% $16,971,230
Driehaus Capital Management LLC 3% 5,170,284 0.1% $15,045,526
Venrock Adviser, LLC 2.9% 5,106,337 0.72% $14,859,441
RA CAPITAL MANAGEMENT, L.P. 2.8% 4,901,960 0.14% $14,264,704
Logos Global Management LP 2.5% 4,411,764 0.78% $12,838,233
Catalio Capital Management, LP 2.2% 3,921,568 2.1% $11,411,763
PERCEPTIVE ADVISORS LLC 2% 3,431,372 0.19% $9,985,293
Nantahala Capital Management, LLC 1.7% 3,004,848 0.49% $8,744,107
NEXTBio Capital Management LP 1.7% 2,923,937 3.6% $8,508,657
Deep Track Capital, LP 1.4% 2,450,980 0.12% $7,132,352
ADAGE CAPITAL PARTNERS GP, L.L.C. 1.4% 2,450,980 0.01% $7,132,352
Woodline Partners LP 0.8% 1,404,901 0.01% $4,088,262
Foresite Capital Management VI LLC 0.7% 1,225,490 0.63% $3,566,176
Affinity Asset Advisors, LLC 0.53% 934,412 0.15% $2,719,139
SummitTX Capital, L.P. 0.38% 662,079 0.05% $1,926,650
Parkman Healthcare Partners LLC 0.17% 298,791 0.08% $869,482
DIADEMA PARTNERS LP 0.14% 245,098 0.33% $713,235
MARSHALL WACE, LLP 0.12% 210,747 0% $613,275

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
34
Headline period
Q3 2026
Rows shown
1-25 of 34
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 122,291,982 $355,869,666 +$326,240,700 $2.91 35
2026 Q2 10,728,883 $18,985,880 +$5,294,822 $1.77 27
2026 Q1 7,871,783 $8,677,875 -$1,722,017 $1.11 26
2025 Q4 9,342,877 $18,125,113 +$502 $1.94 22
2025 Q3 9,194,576 $17,653,167 -$1,951,360 $1.92 21
2025 Q2 10,211,002 $19,401,301 +$12,863 $1.90 19
2025 Q1 10,222,258 $17,377,838 +$4,637,662 $1.70 18
2024 Q4 7,494,222 $15,902,006 +$4,661,706 $2.12 14
2024 Q3 5,323,228 $10,112,228 +$57,454 $1.90 17
2024 Q2 5,292,989 $9,745,202 +$1,916,835 $1.84 14
2024 Q1 4,259,308 $7,113,387 +$404,057 $1.67 14
2023 Q4 4,062,589 $2,437,015 +$887,868 $0.60 9
2023 Q3 2,579,003 $1,870,234 +$4,206 $0.72 11
2023 Q2 2,569,162 $2,166,115 -$314,934 $0.84 10
2023 Q1 2,830,846 $3,283,550 -$215,433 $1.16 8
2022 Q4 566,752 $413,272 -$1,176,817 $0.73 10
2022 Q3 4,663,496 $4,850,000 -$254,655 $1.04 8
2022 Q2 4,916,394 $6,538,000 -$45,964 $1.33 9
2022 Q1 4,949,328 $14,203,000 -$2,021,499 $2.86 10
2021 Q4 5,655,346 $15,920,000 -$38,159 $2.82 10
2021 Q3 5,665,990 $26,717,000 +$2,489,496 $4.71 13
2021 Q2 5,111,468 $30,566,000 +$18,924,636 $5.98 14
2021 Q1 1,986,053 $7,567,000 +$563,572 $3.81 7
2020 Q4 1,857,733 $2,008,000 -$82,677 $1.09 5
2020 Q3 1,905,237 $2,363,000 -$160,746 $1.24 5
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .